For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
13
views
47
references
 Top references
cited by
13
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      637
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pathophysiology of copeptin in kidney disease and hypertension

      review-article
      Author(s): 1 , 2 ,
      Publication date (Electronic):
      Journal: Clinical Hypertension
      Publisher: BioMed Central
      Keywords: Albuminuria, Copeptin, Kidney damage, Chronic kidney disease

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Copeptin is derived from the cleavage of the precursor of arginine vasopressin (AVP), produced in an equimolar ratio in hypothalamus and processed during axonal transport AVP is an unstable peptide and has a short half-life of 5–20 min. Unlike AVP, copeptin is a stable molecule and can easily be measured. Recent evidence suggest that increased copeptin levels have been associated with worse outcomes in various clinical conditions including chronic kidney disease (CKD) and hypertension. In this review, the data regarding copeptin with kidney function (evaluated as glomerular filtration rate, increased albumin/protein excretion or both) and hypertension with regard to performed studies, prognosis and pathogenesis was summarised.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          Vasopressin: a novel target for the prevention and retardation of kidney disease?

          Eberhard Ritz, Nadine Bouby, Lise Bankir (2013)
          After several decades during which little attention was paid to vasopressin and/or urine concentration in clinical practice, interest in vasopressin has renewed with the availability of new, potent, orally active vasopressin-receptor antagonists--the vaptans--and with the results of epidemiological studies evaluating copeptin (a surrogate marker of vasopressin) in large population-based cohorts. Several experimental studies in rats and mice had previously shown that vasopressin, acting via vasopressin V2 antidiuretic receptors, contributes to the progression of chronic kidney disease; in particular, to autosomal dominant polycystic kidney disease. New epidemiological studies now suggest a role for vasopressin in the pathogenesis of diabetes mellitus and metabolic disorders via activation of hepatic V1a and/or pancreatic islet V1b receptors. The first part of this Review describes the adverse effects of vasopressin, as revealed by clinical and experimental studies in kidney diseases, hypertension, diabetes and the metabolic syndrome. The second part provides insights into vasopressin physiology and pathophysiology that may be relevant to the understanding of these adverse effects and that are linked to the excretion of concentrated nitrogen wastes and associated hyperfiltration. Collectively, the studies reviewed here suggest that more attention should be given to the vasopressin-thirst-urine concentration axis in clinical investigations and in patient care. Whether selective blockade of the different vasopressin receptors may provide therapeutic benefits beyond their present indication in hyponatraemia requires new clinical trials.
          Article 0 comments Cited 74 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort.

            Esther Meijer, Stephan Bakker, Nynke Halbesma … (2010)
            Urinary albumin excretion is a powerful predictor of progressive cardiovascular and renal disease. In rats and humans, administration of a synthetic vasopressin analogue, 1-desamino-8-D-arginine-vasopressin, increases urinary albumin excretion; however, it is unknown if endogenous vasopressin levels influence albumin excretion. To determine this we measured copeptin, a marker of endogenous vasopressin levels, and its association with urinary albumin excretion in 7593 patients in the PREVEND study, a prospective population based, observational cohort. Urinary albumin excretion was measured in two consecutive 24-h urine samples by nephelometry while copeptin was measured by an immunoassay. Median copeptin concentrations were significantly higher in males than females and high levels were associated with significantly lower 24-h urine volumes of high osmolarity. With increasing quintiles of copeptin levels, the percentage of microalbuminuric subjects increased from 13 to 25 for males and from 8 to15 for females. This association was independent of age and other potential confounders; however, we found an interaction between age and copeptin in their association with urinary albumin excretion. Our study shows that plasma copeptin levels are associated with microalbuminuria, consistent with the hypothesis that vasopressin is involved in urinary albumin excretion. If future studies show that this association is causal, then drinking more water or pharmacological intervention to decrease plasma vasopressin may have beneficial effects on the kidney, especially in the elderly.
            Article 0 comments Cited 46 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Copeptin: a biomarker of cardiovascular and renal function.

              Nils Morgenthaler (2010)
              Arginine vasopressin (AVP or antidiuretic hormone) is one of the key hormones in the human body responsible for a variety of cardiovascular and renal functions. It has so far escaped introduction into the routine clinical laboratory due to technical difficulties and preanalytical errors. Copeptin, the C-terminal part of the AVP precursor peptide, was found to be a stable and sensitive surrogate marker for AVP release. Copeptin behaves in a similar manner to mature AVP in the circulation, with respect to osmotic stimuli and hypotension. During the past years, copeptin measurement has been shown to be of interest in a variety of clinical indications, including cardiovascular diseases such as heart failure, myocardial infarction, and stroke. This review summarizes the recent progress on the diagnostic use of copeptin in cardiovascular and renal diseases and discusses the potential use of copeptin measurement in the context of therapeutic interventions with vasopressin receptor antagonists.
              Article 0 comments Cited 45 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Baris Afsar: afsarbrs@yahoo.com
                Journal
                Journal ID (nlm-ta): Clin Hypertens
                Journal ID (iso-abbrev): Clin Hypertens
                Title: Clinical Hypertension
                Publisher: BioMed Central (London )
                ISSN (Electronic): 2056-5909
                Publication date (Electronic): 13 June 2017
                Publication date PMC-release: 13 June 2017
                Publication date Collection: 2017
                Volume: 23
                Electronic Location Identifier: 13
                Affiliations
                [1 ]ISNI 0000 0004 0527 3171, GRID grid.45978.37, Department of Internal Medicine, Nephrology Division, , Suleyman Demirel University, Faculty of Medicine, ; Isparta, Turkey
                [2 ]ISNI 0000 0004 0527 3171, GRID grid.45978.37, , Suleyman Demirel University, Çünür, Doğu yerleşkesi, Isparta Merkez/Isparta, ; Postal Code: 32260 Isparta, Turkey
                Article
                Publisher ID: 68
                DOI: 10.1186/s40885-017-0068-y
                PMC ID: 5469179
                PubMed ID: 28638629
                SO-VID: 49227576-de6c-4521-846c-dbae727727c4
                Copyright © © The Author(s). 2017
                License:

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                Date received : 2 December 2016
                Date accepted : 23 February 2017
                Categories
                Subject: Review
                Custom metadata
                issue-copyright-statement © The Author(s) 2017

                Keywords: albuminuria,copeptin,kidney damage,chronic kidney disease
                Data availability:
                Keywords: albuminuria, copeptin, kidney damage, chronic kidney disease

                Comments

                Comment on this article

                scite_

                Similar content637

                See all similar

                Cited by12

                See all cited by

                Most referenced authors477

                See all reference authors